(Boursier.com) — Novacyt confirme que le chiffre d'affaires des activités poursuivies à fin d'année s'élève à environ 13,7 ME, soit une croissance de 9% à taux de change constant sur une base consolidée par rapport à 2017. La base consolidée comprend les business units Primerdesign et Lab21 ainsi que 1 ME de ventes de produits Omega depuis l'acquisition de cet actif le 28 juin 2018. Le solde de trésorerie de fin d'année s'élève à environ 1,1 ME. En excluant l'acquisition d'Omega-ID, la croissance de l'activité coeur de métier pour l'année est de 1% à taux de change constant, sans compter 1 ME de commandes qui devraient maintenant être facturées en 2019. Novacyt démarre donc l'année 2019 avec un carnet de commandes "encourageant", comprenant une demande supplémentaire d'instruments Q16 en provenance de Chine, sous réserve du délai de fabrication. La société ajoute que la vente potentielle de la business unit NOVAprep, qui a déjà fait l'objet de multiples marques d'intérêt, "continue de progresser".

Novacyt confirme un chiffre d'affaires de 13,7 ME en 2018

Novacyt : Trading Update
Message :
Regulatory News:
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist      in clinical diagnostics products, on the 11 December announced its      decision to sell the NOVAprep® business unit. As a result, the Company      confirms that NOVAprep® will be treated as a discontinued operation      under IFRS in the 2018 full year results. The Company provides shareholders with a trading update and an early      view of the anticipated impact of the IFRS accounting treatment, subject      to final audit approval. The Company estimates revenue from continuing operations, which will      include the Primerdesign and Lab21 business units, of €13.7m to €14.4m,      which compares to the market consensus of €15.85m. The shortfall in      sales is primarily due to shipping of confirmed tender orders amounting      to more than €1.0m slipping into the next financial period. In addition,      due to favourable changes in product mix and an increased focus on cost      control, gross and EBITDA margins for both Primerdesign and Lab21 are      expected to improve in 2018, versus 2017. On a forward basis, the discontinued loss-making NOVAprep® business      unit, which continues to be cash consumptive for the Group, will be      excluded from continuing operations and consequently the reported      revenue and operating results. As a result, the EBITDA (excluding      NOVAprep®) for the Group is expected to be positive for the full year,      which is being driven by the profitable core units of Primerdesign and      Lab21. The impact of the NOVAprep® business unit being classified as held for      sale is also expected to result in a restatement of the full year 2017      financial results of the Novacyt Group, excluding the NOVAprep® business      unit, which will be presented at the same time as the full year 2018      results. Cash at the end of the year is expected to be between €0.8m and €1.0m      and any cash from the future sale of the NOVAprep® business unit, as      well as the Company’s clinical laboratory unit (the “Clinical Lab”) will      be additive. Update on sales process of Clinical Lab and NOVAprep® business units
The sale of the Clinical Lab business continues to progress well, with      firm proposals now received from multiple parties. Due diligence is      currently underway and the Board is now optimistic of completing a sale      by the end of the first quarter 2019. The sale of the NOVAprep® business unit is also making good early      progress with multiple expressions of interest. The Company expects to      update shareholders on this sale process during the first quarter of      2019. There can be no certainty that these offers and interest will result in      a successful sale of either business unit. Outlook
The restructure of the Group with the sale of the Clinical Lab and      NOVAprep® will allow Novacyt to fully focus on the diagnostic product      businesses comprising Primerdesign and Lab21 Products. Consequently, the      increased focus should improve sales growth and accelerate the Group’s      future profitability. A significant number of new sales tenders have been awarded during the second half of 2018, which will now be fulfilled during the first half      of 2019. In addition, the full integration of the acquisition of the      profitable Omega Infectious Disease assets are also expected to be      realised in 2019, which is anticipated to add approximately €2.5m of      revenue to the Group and a strong EBITDA through the achievement of      expected cost synergies. China continues to be a significant growth area as recently reported on      6 December 2018 with a q16 instrument order for 100 units. Discussions      are now underway for further sales of material numbers of units in 2019. On 21 December 2018, Novacyt also announced the launch of its new      CE-Marked molecular products, which is expected to generate new sales in      2019 through its own sales channels. In addition, Novacyt is focused on      developing more strategic business-to-business partnerships such as the      one announced with Genesis Diagnostics on 22 November 2018, which      expands Novacyt’s reach into the US market. Graham Mullis, Group CEO of Novacyt, commented:
“We are disappointed that sales are behind our expectations but are      pleased with the improvements we expect to realise in the gross and      EBITDA margins of our core business units and we remain confident in      achieving our EBITDA profitability target for the full year. The      strategic review and subsequent restructure of the Group are also key      steps in streamlining Novacyt, enabling us to maximise our potential in      diagnostic reagent products. We firmly believe the opportunity to grow      and scale our molecular and protein reagent businesses is significant      and we remain committed to our three strategic pillars of organic,      acquisitive and R&D based growth. The anticipated proceeds from the      disposal of non-core assets will be invested organically to accelerate      and enhance profitability of the core Group.”
- End –
About Novacyt Group
The Novacyt Group is a rapidly growing, international diagnostics      group with a growing portfolio of cancer and infectious disease products      and services. Through its proprietary technology platform, NOVAPrep®,      and molecular platform, genesig®, Novacyt is able to provide an      extensive range of oncology and infectious disease diagnostic products      across an extensive international distributor network. The Group has      diversified sales from diagnostic reagents used in oncology,      microbiology, haematology and serology markets, and its global customers      and partners include major corporates. For more information please refer to the website: www.novacyt.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181223005019/en/
© Business Wire 2018

Novacyt : Trading Update

05:07 EST 14 Dec 2018 | BioPortfolio Reports
Summary
Lab21 Ltd Lab21, a subsidiary of Novacyt SA, is a clinical laboratory that offers clinical diagnostic testing services. The company develops molecular diagnostics for oncology and virology. Its oncology includes KRAS, EGFR, BRAF, ALK, RASRAF, BRCA , prostate cancer, among others. Lab21's virology includes HIV viral load, tropism by genotype, genotyping, HIV TDM, hepatitis TDM, and others. The company supplies diagnostic kits and reagents on infectious diseases for blood donor screening and routine clinical markets. It provides clinical laboratory testing services to clinicians, healthcare providers, patients, pharmaceutical and biotechnology companies. Lab21 is headquartered in Cambridge, the UK. Lab21 Ltd  Medical Equipment  Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Medical eTrack deals database, and primary and secondary research. Scope
Financial Deals  Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year  Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type  Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region  Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector  Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals  Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description  A brief description of the company's operations. Key Employees  A list of the key executives of the company. Important Locations and Subsidiaries  A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors  A list of the key competitors of the company. Key Recent Developments  A brief on recent news about the company. Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Lab21 Ltd  Medical Equipment  Deals and Alliances Profile Report Updated 06122018 Prices from USD $250

NEW YORK (GenomeWeb) — French diagnostics firm Novacyt said today that it plans to divest its Novaprep cytology business and clinical laboratory operations in order to focus on in vitro diagnostic product development and its profitable Lab21 and Primerdesign diagnostic reagent units. To read the full story....

Novacyt to Sell Cytology, Clinical Lab Units

09:22 EDT 12 Aug 2018 | BioPortfolio Reports
Summary
Lab21 Ltd Lab21, a subsidiary of Novacyt SA is a clinical laboratory that provides clinical diagnostic testing services. The company develops molecular diagnostics for oncology , HIV and viral hepatitis, drug management needs; and diagnostic kits and reagents including syphilis, malaria, human cytomegalovirus, blood donor screening, virology, enzyme immunoassay, bulk material, febrile stained antigen, latex serology, and oncology tests. It supplies diagnostic kits and reagents which concentrates on infectious diseases for blood donor screening and routine clinical markets. Lab21's products are used in the therapeutic areas of latex serology, virology, oncology and others. It provides clinical laboratory testing services to clinicians, healthcare providers, patients, pharmaceutical and biotechnology companies. Lab21 is headquartered in Cambridge, the UK. Lab21 Ltd  Medical Equipment  Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Medical eTrack deals database, and primary and secondary research. Scope
Financial Deals  Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year  Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type  Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region  Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector  Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals  Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description  A brief description of the company's operations. Key Employees  A list of the key executives of the company. Important Locations and Subsidiaries  A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors  A list of the key competitors of the company. Key Recent Developments  A brief on recent news about the company. Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy
The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company
Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research
Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

Lab21 Ltd  Medical Equipment  Deals and Alliances Profile Report Updated 11052018 Prices from USD $250

MDxHealth (Nasdaq and Euronext Brussels: MDXH) is a company developing and commercializing diagnostic assays for the early detection and characterization of cancer based on the detection of DNA methylation.

MDxHealth

`` Lab21 is the ideal partner to bring SelectMDx to UK physicians and patients for the first time , helping to improve both the quality of care and outcomes for those suspected of harboring prostate cancer . ''

MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom

IntegraGen's mission is to translate molecular research to clinical practice through the identification of novel genetic biomarkers and the subsequent commercialization of molecular diagnostic tests for autism and oncology based on these discoveries.On July 9th, 2020 IntegraGen was acquired by OncoDNA at a valuation of $16.36M.

IntegraGen

BD is a medical technology company that manufactures and sells a broad range of supplies, devices, and systems for use by healthcare professionals, medical research institutions, industry, and the general public.

Co-Diagnostics (NASDAQ: CODX) is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems ("MDx device").

Co-Diagnostics

Cardiff University

PBD Biotech

Bayer

Visible Genetics

Virco

Glaxo Wellcome

Visiontec

Biocompatibles

Selah Genomics

Selah Technologies

IRIX Pharmaceuticals

Ieso Digital Health

PsiOxus Therapeutics

Alliance Pharma

viO HealthTech

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

Lab21 is a healthcare diagnostics company which specializes in providing patients, doctors, hospitals and healthcare providers with important high quality diagnostic information for disease identification, disease predisposition and personalized medicine, to help manage health problems.

Name	Work History	Title	Status
Berwyn Clarke	Cardiff University, PBD Biotech, Bayer, Visible Genetics, Virco, and Glaxo Wellcome	Founder	Current
Graham Mullis	Visiontec, and Biocompatibles	Chief Executive Officer	Former
Jeremy Walker		Chief Executive Officer	Former
Michael Bolick	Selah Genomics, Selah Technologies, and IRIX Pharmaceuticals	President	Former
Maddy Kennedy	Ieso Digital Health, PsiOxus Therapeutics, Alliance Pharma, and viO HealthTech	Chief Financial Officer	Former

Name	Berwyn Clarke	Graham Mullis	Jeremy Walker	Michael Bolick	Maddy Kennedy
Work History	Cardiff University, PBD Biotech, Bayer, Visible Genetics, Virco, and Glaxo Wellcome	Visiontec, and Biocompatibles		Selah Genomics, Selah Technologies, and IRIX Pharmaceuticals	Ieso Digital Health, PsiOxus Therapeutics, Alliance Pharma, and viO HealthTech
Title	Founder	Chief Executive Officer	Chief Executive Officer	President	Chief Financial Officer
Status	Current	Former	Former	Former	Former

Wells Fargo Success Story

3M Success Story

Platform Overview

Lab21

Executives

Lab21 Management Team

6 Team Members

Discover the right solution for your team